Jonathan Lambert

Jonathan Lambert is a journalist based in Washington, D.C., who covers the intersection of science, health, and policy. He holds a master's degree in neurobiology and behavior from Cornell University. He has written for Science News, NPR, Grid, and Quanta Magazine.

Biography:  https://www.theatlantic.com/author/jonathan-lambert/

68%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

0%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

50%

Examples:

  • FDA is set to discuss whether to approve the first psychedelic drug for PTSD treatment
  • MDMA-assisted therapy showed promising results in clinical trials with PTSD patients

Deceptions

100%

Examples:

No current examples available.

Recent Articles

FDA Panel Rejects MDMA-Assisted Therapy for PTSD: Rigorous Clinical Trials and Transparency Needed

FDA Panel Rejects MDMA-Assisted Therapy for PTSD: Rigorous Clinical Trials and Transparency Needed

Broke On: Monday, 03 June 2024 FDA advisory committee votes against MDMA-assisted therapy for PTSD due to concerns over flawed clinical trials and potential misconduct, jeopardizing Lykos Therapeutics' FDA approval and slowing down the expansion of the psychedelics market. Patients with debilitating PTSD symptoms continue their search for effective treatments as experts remain optimistic about psychedelics' potential in mental health disorders.